To prove JNK/MAPK pathway is required for the treatment of tamoxifen on NAFLD, we applied a pharmacological JNK activator-anisomycin (ANI).30 Male mice fed with MCD diet were injected with 100 mg/kg tamoxifen and 50 mg/kg ANI for 5 consecutive days (Fig. 7a). Here, MAPK8 is linked to metabolic dysfunction-associated steatotic liver disease.